JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schütte, H.
Right arrow Articles by Seeger, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schütte, H.
Right arrow Articles by Seeger, W.

Vol. 282, Issue 2, 985-994, 1997

Efficiency of Aerosolized Nitric Oxide Donor Drugs to Achieve Sustained Pulmonary Vasodilation1

Hartwig Schütte, Friedrich Grimminger, Jörg Otterbein, Reiner Spriestersbach, Konstantin Mayer, Dieter Walmrath and Werner Seeger

Department of Internal Medicine, Justus-Liebig University, Klinikstrasse 36, 35385 Giessen, Germany

Inhalation of nitric oxide (NO) causes selective pulmonary vasodilation, but demands continuous supply of the gaseous agent. We investigated the suitability of aerosolization of NO-donor drugs for achieving sustained reduction of pulmonary vascular tone. In buffer-perfused rabbit lungs, stable pulmonary hypertension was achieved by continuous infusion of the thromboxane-analogue U46619. The NO-donor drugs molsidomine, 3-morpholinosydnone-imine (SIN-1), sodium nitroprusside (SNP) and glyceryl-trinitrate reduced the pulmonary hypertension in a dose-dependent fashion, whether admixed to the perfusate or inhaled as alveolar-accessible aerosol particles (aerosolization time 3-6 min), with an efficiency ranking of SNP > SIN-1 >>  molsidomine and glyceryl-trinitrate. Notably, nearly identical dose-response curves were obtained when corresponding molar quantities of the most potent agents, SNP and SIN-1, were applied either via transbronchial or via intravascular routes, with respect to rapidity of onset, extent (pressure reduction to near baseline) and duration (>90 min) of vasorelaxation. Appearance of sydnonimines in the perfusate after aerosolization and reduction of SIN-1 efficacy when nebulized in nonrecirculatingly perfused lungs demonstrated substantial entry of this prodrug into the vascular space after alveolar deposition. In contrast, undiminished vasodilatory efficacy of aerosolized SNP under conditions of non-recirculating perfusion suggested predominant efficacy via local NO release for this agent. We conclude that short aerosolization maneuvers of NO-donor drugs are suitable to achieve dose-dependent, extensive and sustained vasodilation in the pulmonary circulation, thus offering a new therapeutic approach in pulmonary hypertension.

Copyright © by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Br J AnaesthHome page
P. Goyal, U. Kiran, S. Chauhan, R. Juneja, and M. Choudhary
Efficacy of nitroglycerin inhalation in reducing pulmonary arterial hypertension in children with congenital heart disease
Br. J. Anaesth., August 1, 2006; 97(2): 208 - 214.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
B. M. Tsai, M. Wang, M. W. Turrentine, Y. Mahomed, J. W. Brown, and D. R. Meldrum
Hypoxic pulmonary vasoconstriction in cardiothoracic surgery: basic mechanisms to potential therapies
Ann. Thorac. Surg., July 1, 2004; 78(1): 360 - 368.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. Y. Kirov, O. V. Evgenov, V. N. Kuklin, L. Virag, P. Pacher, G. J. Southan, A. L. Salzman, C. Szabo, and L. J. Bjertnaes
Aerosolized Linear Polyethylenimine-Nitric Oxide/Nucleophile Adduct Attenuates Endotoxin-induced Lung Injury in Sheep
Am. J. Respir. Crit. Care Med., December 1, 2002; 166(11): 1436 - 1442.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
F. C Blumberg, C. Lorenz, K. Wolf, P. Sandner, G. A.J Riegger, and M. Pfeifer
Increased pulmonary prostacyclin synthesis in rats with chronic hypoxic pulmonary hypertension
Cardiovasc Res, July 1, 2002; 55(1): 171 - 177.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
H. Schutte, A. Lockinger, W. Seeger, and F. Grimminger
Aerosolized PGE1, PGI2 and nitroprusside protect against vascular leakage in lung ischaemia-reperfusion
Eur. Respir. J., July 1, 2001; 18(1): 15 - 22.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
F. C. Blumberg, K. Wolf, P. Sandner, C. Lorenz, G. A. J. Riegger, and M. Pfeifer
The NO donor molsidomine reduces endothelin-1 gene expression in chronic hypoxic rat lungs
Am J Physiol Lung Cell Mol Physiol, February 1, 2001; 280(2): L258 - L263.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
M. Ermert, M. Merkle, R. Mootz, F. Grimminger, W. Seeger, and L. Ermert
Endotoxin priming of the cyclooxygenase-2-thromboxane axis in isolated rat lungs
Am J Physiol Lung Cell Mol Physiol, June 1, 2000; 278(6): L1195 - L1203.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
V. G. NIELSEN, M. S. BAIRD, L. CHEN, and S. MATALON
DETANONOate, a Nitric Oxide Donor, Decreases Amiloride-sensitive Alveolar Fluid Clearance in Rabbits
Am. J. Respir. Crit. Care Med., April 1, 2000; 161(4): 1154 - 1160.
[Abstract] [Full Text]

Home page
 J. Appl. Physiol.Home page
D. J. Horstman, L. G. Fischer, P. C. Kouretas, R. L. Hannan, and G. F. Rich
Role of nitric oxide in heparin-induced attenuation of hypoxic pulmonary vascular remodeling
J Appl Physiol, May 1, 2002; 92(5): 2012 - 2018.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics.